103 related articles for article (PubMed ID: 6628467)
1. Clinical significance of routine follow-up examinations in patients with metastatic cancer of the prostate under hormone treatment.
Fosså SD; Heilo A; Lindegaard M; Skinningrud A; Ous S
Eur Urol; 1983; 9(5):262-6. PubMed ID: 6628467
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
4. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL
BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971
[TBL] [Abstract][Full Text] [Related]
5. Bone imaging and serum phosphatases in prostatic carcinoma.
Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
Merrick MV; Ding CL; Chisholm GD; Elton RA
Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
[TBL] [Abstract][Full Text] [Related]
7. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
8. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
9. [The diagnostic value of radiological, nuclear medicine and biochemical methods for detection of bone metastases in carcinoma of the prostate (author's transl)].
Rost A; Fiedler U; Marshall F; Koppenhagen K
Radiologe; 1977 Jun; 17(6):249-55. PubMed ID: 887744
[TBL] [Abstract][Full Text] [Related]
10. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.
Pollen JJ; Witztum KF; Ashburn WL
AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903
[TBL] [Abstract][Full Text] [Related]
11. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
12. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
[TBL] [Abstract][Full Text] [Related]
14. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
[TBL] [Abstract][Full Text] [Related]
15. Follow-up in prostate cancer patients: which parameters are necessary?
Strohmaier WL; Keller T; Bichler KH
Eur Urol; 1999 Jan; 35(1):21-5. PubMed ID: 9933790
[TBL] [Abstract][Full Text] [Related]
16. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
17. Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy--comparison with tumor markers and bone X-ray.
Koizumi K; Uchiyama G; Komatsu H
Ann Nucl Med; 1994 Nov; 8(4):225-30. PubMed ID: 7535550
[TBL] [Abstract][Full Text] [Related]
18. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
[No Abstract] [Full Text] [Related]
19. Serial Fluorine-18 bone scans in the follow-up of carcinoma of the prostate.
Buck AC; Chisholm GD; Merrick MV; Lavender JP
Br J Urol; 1975 Jun; 47(3):287-94. PubMed ID: 1095103
[TBL] [Abstract][Full Text] [Related]
20. Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity.
Reikerås O; Due J; Sundsfjord JA
Int Urol Nephrol; 1988; 20(1):51-4. PubMed ID: 3283071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]